Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin and Velcade in relapsed/refractory mantle cell lymphoma
NCT01497275Phase 2Terminated
- Sponsor
- Duke University
- Start
- Feb 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan and bortezomib in mantle cell lymphoma (MCL), sponsored by Duke University. Primary endpoint: Overall Response Rate at 3 months. Started Feb 2012; status: terminated.
02
Drugs
ibritumomab tiuxetanbortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01497275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497275.